izvor podataka: crosbi
✓
News from ASCO 2018 (CROSBI ID 292688)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Balic, Marija ; Dedić Plavetić, Natalija ; De Mattos-Arruda, Leticia ; Gampenrieder, Simon
News from ASCO 2018 // Breast care, 13 (2018), 4; 298-302. doi: 10.1159/000491564
Podaci o odgovornosti
Balic, Marija ; Dedić Plavetić, Natalija ; De Mattos-Arruda, Leticia ; Gampenrieder, Simon
engleski
News from ASCO 2018
News from ASCO 2018 congress. In the plenary session at the ASCO Annual Meeting 2018, Joseph A. Sparano has presented results of the TAILORx trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor(HR)-positive/HER2- negative node-negative breast cancer and intermediate prognosis based on 21-gene recurrence score (RS).
ASCO 2018
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti
Poveznice
Indeksiranost
